While immunotherapy would not be a typical therapeutic consideration in RDD since it typically behaves as low-grade indolent neoplasm and also responds to MEK inhibitors, it is intriguing to consider checkpoint blockade as a possible adjunct to MEK or BRAF inhibitor therapy in more severe cases of RDD. This evidence concerns the gene BRAF and neoplasm.